GE Healthcare Technologies (GEHC) is seen as a top stock for long-term investors given its strong value and momentum. GEHC is bolstering its presence in the global market with a landmark CT Scanner deal in Indonesia expected to bring lifesaving scans closer to 280M Indonesians. Additionally, the company is laying a $750M loan for Intelerad, indicating significant investment in hyper-focused segments.
This positive sentiment is shared by several entities who are increasing their stakes in GEHC, such as Salem Investment Counselors, Thrivent Financial for Lutherans, Caldwell Trust, and National Bank of Canada. Despite some fluctuations in stock performance, the company's overall valuation shows robust growth following recent share price movements, product launches, and the emerging AI partnerships.
The unveiling of GEMINI-RT to advance AI-guided radiation therapy signifies GEHC's commitment to Oncology innovation. Yet, the purchase of Intelerad for $2.3 billion underscores the company's ambition to expand in outpatient care. Despite tariff-induced pressures, it still managed to meet second-quarter 2025 earnings estimates, supported by a resilient profit margin jump to 10.9%. Several financial institutions recognize the company's attractiveness, reaffirming their 'buy' ratings and increasing the target price amid strong orders and backlog.
Ge Healthcare Technologies GEHC News Analytics from Tue, 13 May 2025 07:00:00 GMT to Sat, 20 Dec 2025 11:13:29 GMT - Rating 9 - Innovation 8 - Information 9 - Rumor -2
